This study involved 78 participants taking 150 mg of Ibandronate once a month for the investigation of the drug efficacy and safety. Ibandronate had a strong antiresorptive action that decreased 67.9 per cent of bone resorption. The total cases of unwanted effect were 21 that showed the common adverse events like other bisphosphonate. The most common events were flu-like symptom (8.75%) and dyspepsia (7.5%) which occurred at the first tablet. Most participants subsided after the following months, but only one case persisted in these symptoms through the study period while the others had a myalgia, diarrhea and burning of epigastric in percent of 6.25, 2.5, 1.25 respectively. Ibandronate (150 mg) showed the strong antiresorptive effect and good compliance for taking once a month.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background Fragility fractures, often caused by osteoporosis, are a major public health concern among the growing population of the United Kingdom (UK). In addition to being a major source of illness and mortality, the rising incidence of osteoporosis places a heavy strain on healthcare systems if it is not adequately managed. In order to lower the risk of additional fractures, current guidelines place a strong emphasis on the timely evaluation and treatment of fragility fractures.
View Article and Find Full Text PDFPrediction of Medication-Related Osteonecrosis of the Jaw in Patients Receiving Antiresorptive Therapy Using Machine Learning Models.
J Oral Maxillofac Surg
December 2024
Assistant Professor, Research and Data Development, The Securities and Exchange Commission, Bangkok, Thailand.
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication associated with the use of antiresorptive agents, impacting patient quality of life and treatment outcomes. Predictive modeling may aid in a better understanding of MRONJ development.
Purpose: The study aimed to evaluate machine learning (ML)-based models for predicting MRONJ in patients receiving antiresorptive therapy.
Geranylgeranyl diphosphate synthase inhibition impairs osteoclast differentiation, morphology, and resorptive activity.
JBMR Plus
January 2025
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Article Synopsis
- Nitrogen bisphosphonates like zoledronic acid treat osteolytic bone diseases by targeting farnesyl diphosphate synthase (FDPS), but their strong bone affinity limits their systemic use.
- RAM2061, a novel GGDPS inhibitor, shows promising drug-like qualities, such as prolonged half-life and anti-cancer effects in mouse models, and impacts osteoclast biology by disrupting differentiation and function.
- Although RAM2061 treatment didn't significantly affect overall bone turnover in mice, it reduced mature osteoclast numbers, signaling its potential for further investigation in bone remodeling therapies.
Investigating the protective effect of loganin in ovariectomy‑induced bone loss through network pharmacology and molecular docking.
Exp Ther Med
November 2024
Department of Endocrinology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R. China.
Loganin, a major iridoid glycoside derived from , exerts strong anti-inflammatory property. The present study aimed to investigate the underlying mechanism of loganin to reduce estrogen deficiency-induced bone loss through a combination of network pharmacology, molecular docking and validation. First, the drug targets and structural interactions of loganin with osteoclasts on postmenopausal osteoporosis (PMOP) were predicted through network pharmacology and molecular docking.
View Article and Find Full Text PDFImmune regulatory and anti-resorptive activities of tanshinone IIA sulfonate attenuates rheumatoid arthritis in mice.
Br J Pharmacol
December 2024
Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada.
Background And Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and painful joint destruction. Current treatments are helpful in RA remission, but strong immunosuppressive activity and patient resistance are clinical issues. This study explores a dual-action inhibitor, possessing both anti-inflammatory and anti-resorptive properties, as a novel treatment for RA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!